Finger stick blood test to assess post vaccination SARS-CoV-2 neutralizing antibody response against variants

Abstract

There is clinical need for a quantifiable point-of-care (PoC) SARS-CoV-2 neutralizing antibody (nAb) test that is adaptable with the pandemic’s changing landscape. Here, we present a rapid and semi-quantitative nAb test that uses finger stick or venous blood to assess the nAb response of vaccinated population against wild-type, alpha, beta, gamma, and delta variant receptor binding domains. It captures a clinically relevant range of nAb levels, and effectively differentiates pre-vaccination, post 1st dose and post 2nd dose vaccination samples within 10 minutes. The data observed against alpha, beta, gamma, and delta variants agrees with published results evaluated in established serology tests. Finally, our test revealed a substantial reduction in nAb level for beta, gamma, and delta variants between early BNT162b2 vaccination group (within 3 months) and later vaccination group (post 3 months). This test is highly suited for PoC settings and provides an insightful nAb response in a post-vaccinated population.

Image‐based real‐timefeedback control of magnetic digital microfluidics by artificialintelligence‐empoweredrapid object detector for automated in vitro diagnostics

“…1 IVD plays an essential role in patient care and public health; billions of molecular IVD tests (PCR tests) and immunodiagnostic IVD tests (antibody tests) have been performed to contain global COVID-19 pandemic. [2][3][4][5][6] One of the riskiest factors involving IVD is sample handling, which may cause accidental exposure to contagious pathogens among healthcare workers. Automated IVD can reduce such risks by minimizing manual interventions required to handle hazardous biological samples.…”